Risultati di ricerca - Portale di modelli di dati medici (MDM-Portal)

Filtra i risultati della ricerca
Seleziona modelli di dati

Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

143 Risultati di ricerca.

ECG Evidence of myocardial ischemia/infarction GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 1 ItemGroup, 13 elementi, 1 linguaggio

ItemGroup: ECG Evidence of myocardial ischemia/infarction

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: ECG Evidence of myocardial ischemia/infarction - Repeating form (Scheduled visits)

Cardiac biomarkers GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 1 ItemGroup, 11 elementi, 1 linguaggio

ItemGroup: Cardiac biomarkers

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Cardiac biomarkers - Repeating form (Scheduled visits)

Endpoint death GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 3 itemgroups, 35 elementi, 1 linguaggio

Itemgroups: Investigator section, CEC Section, CEC Status

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Endpoint death

Cardiovascular diagnostic procedures GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 3 itemgroups, 11 elementi, 1 linguaggio

Itemgroups: Cardiovascular diagnostic procedures, Cardiac stress testing, Other cardiac diagnostic procedures

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Cardiovascular diagnostic procedures

Pharmacokinetics GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 1 ItemGroup, 6 elementi, 1 linguaggio

ItemGroup: PK blood sample

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Pharmacokinetics - Repeating form (Scheduled visits)

Hypersensitivity Reaction Record GSK study Chronic Coronary Heart Disease NCT00799903

- 03/01/18 - 1 modulo, 16 itemgroups, 69 elementi, 1 linguaggio

Itemgroups: Event number, Food allergies, Hymenoptera sting allergy, Latex allergy, 5. Penicillin allergy, Cephalosporin allergy, Aspirin allergy, NSAID allergy, ACE inhibitor allergy, Other allergies, Stevens-Johnson syndrome, Toxic epidermal necrolysis, Urticaria (hives), Angioedema, Anaphylactic/Anaphylactoid reaction, Other symptoms of hypersensitivity reaction

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Hypersensitivity Reaction Record - Repeating form (Scheduled visits)

Subject status and major events GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 1 ItemGroup, 12 elementi, 1 linguaggio

ItemGroup: Subject status and major events

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Subject status and major events

End of study Telephone contact GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 1 ItemGroup, 6 elementi, 1 linguaggio

ItemGroup: End of study contact form

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: End of study Telephone contact

Third party survival status GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 2 itemgroups, 8 elementi, 1 linguaggio

Itemgroups: Assessment date, Survival data

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Third party survival status

Third party follow-up GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 2 itemgroups, 6 elementi, 1 linguaggio

Itemgroups: Date of last contact attempt, Contact details

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Third party follow-up - Repeating form (Scheduled/Dynamic visit)

End of study contact GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 1 ItemGroup, 6 elementi, 1 linguaggio

ItemGroup: End of study contact form

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: End of study contact

Alcohol intake (liver alcohol) GSK study Chronic Coronary Heart Disease NCT00799903

- 02/01/18 - 1 modulo, 1 ItemGroup, 3 elementi, 1 linguaggio

ItemGroup: Alcohol intake (liver alcohol)

Study ID: 100601 Clinical Study ID: LPL100601 Study Title: LPL100601, A Clinical Outcomes Study of Darapladib versus Placebo in Subjects with Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00799903 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: darapladib Study Indication: Atherosclerosis Study part: Alcohol intake (liver alcohol)

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.